trial

Specialized Treatment Early in Psychosis (STEP)

NCTId NCT00309452
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 120 (actual)
Sponsored by Yale University
Primary completion 2013-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-03
Primary completion
2013-08
Eligibility
ALL · 16 Years · 45 Years

Interventions & indications

Drugs
Cognitive Behavioral Group TherapyCognitive RemediationMedicationsMFGAssertive case management

Sponsors

Yale UniversityLead Sponsor

Investigators

2
Vinod H Srihari, M.D.Principal Investigator
Scott Woods, M.D.Study Chair

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2013-08
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Behavioral Group Therapy
drug
Cognitive Remediation
drug
Medications
drug
MFG
drug
Assertive case management
drug
lead_sponsor
Yale University
company
indication
Schizophrenia and Disorders With Psychotic Features
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
investigator
Vinod H Srihari, M.D.
person
Scott Woods, M.D.
person